

Safety Data Sheet (SDS) According to the REACH Regulation (EC) No. 1907/2006

Issuing Date: 2015-01-15

Revision Date: 2018-03-26

Version: 3

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Product No Product name Reach registration number 12328 Sunitinib This substance/mixture contains only ingredients which have been registered, or are exempt from registration, according to Regulation (EC) No. 1907/2006.

CAS No

341031-54-7

Contains

Chemical NameIndex No.Butanedioic acid, hydroxy-, (2S)-, compd. withNot ListedN-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyI-1H-pyrrole-3-carboxamide (1:1) (90 - 100%)

Formula	C22H27FN4O2•C4H6O5
Molecular Weight	532.57 g/mol
Other means of identification	12328S

1.2. Relevant identified uses of the substance or mixture and uses advised against

Identified uses

For research use only

1.3. Details of the supplier of the safety data sheet

Importer (Applicable in EU only)	Manufacturer
Cell Signaling Technology Europe B.V.	Cell Signaling Technology, Inc.
Schuttersveld 2	3 Trask Lane
2316 ZA Leiden	Danvers, MA 01923
The Netherlands	United States
TEL: +31 (0)71 7200 200	TEL: +1 978 867 2300
FAX: +31 (0)71 891 0098	FAX: +1 978 867 2400

 Website
 www.cellsignal.com

 E-mail Address
 info@cellsignal.eu

 1.4. Emergency telephone number

CHEMTREC 24 hours a day, 7 days a week, 365 days a year +1 703 527 3887 (INTERNATIONAL) +1 800 424 9300 (NORTH AMERICA)

112

Europe

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

Regulation (EC) No. 1272/2008

Reproductive toxicity	Category 1B - (H360Df)
Specific target organ toxicity - repeated exposure (STOT RE)	Category 1 - (H372)

2.2. Label elements



Signal word Danger

Hazard statement(s)

H360Df - May damage the unborn child. Suspected of damaging fertility H372 - Causes damage to organs through prolonged or repeated exposure if swallowed

Precautionary statement(s)

P201 - Obtain special instructions before use

P202 - Do not handle until all safety precautions have been read and understood

P260 - Do not breathe dust/fume/gas/mist/vapors/spray

P264 - Wash face, hands and any exposed skin thoroughly after handling

P270 - Do not eat, drink or smoke when using this product

P280 - Wear protective gloves/protective clothing/eye protection/face protection

P308 + P313 - IF exposed or concerned: Get medical advice/attention

P405 - Store locked up

P501 - Dispose of contents/container to an approved waste disposal plant

2.3. Other hazards

For the full text of the H-phrases & EUH-phrases mentioned in this Section, see Section 16

SECTION 3: Composition/information on ingredients

3.1 Substances

Synonyms

Formula

Chemical nature

Sunitinib malate; Sutent; ® 1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4dimethyl-, (2S)-hydroxybutanedioate (1:1) $C_{22}H_{27}FN_4O_2 \bullet C_4H_6O_5$ Monoconstituent substance.

Chemical Name Classification CAS No Weight % EC No REACH Registration (1272/2008)Number Carc. 2 (H351) no data available Butanedioic acid, 341031-54-7 100 Repr. 1B (H360Df) hydroxy-, (2S)-, compd. STOT RE 1 (H372) with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydr o-2-oxo-3H-indol-3-yliden e)methyl)-2,4-dimethyl-1 H-pyrrole-3-carboxamide (1:1)

For the full text of the R-phrases mentioned in this Section, see Section 16

SECTION 4: First aid measures

4.1. Description of first aid measures

General advice	Immediate medical attention is required. Show this safety data sheet to the doctor in attendance.
Inhalation	Immediate medical attention is required. Move to fresh air. If not breathing, give artificial respiration.
Skin contact	Immediate medical attention is required. Wash off immediately with soap and plenty of water removing all contaminated clothes and shoes.
Eye contact	Rinse thoroughly with plenty of water, also under the eyelids. Keep eye wide open while rinsing.
Ingestion	Do NOT induce vomiting. Immediate medical attention is required. Never give anything by mouth to an unconscious person. Drink plenty of water.
Protection of first-aiders	Use personal protective equipment. Avoid contact with skin, eyes and clothing.

4.2. Most important symptoms and effects, both acute and delayed

Fatigue. Asthenia. Fever. Diarrhea. Nausea. Vomiting. Abdominal pain. Constipation. hypertension. Peripheral edema. rash. Dry skin. Headache. back pain. Arthralgia. Shortness of breath or cough. dyspnea. Anorexia. mucositis. indigestion. hand-foot syndrome. skin discoloration. altered taste. extremity pain. Bleeding.

4.3. Indication of any immediate medical attention and special treatment needed

SECTION 5: Firefighting measures

5.1. Extinguishing media

Suitable Extinguishing MediaUse extinguishing measures that are appropriate to local circumstances and the
surrounding environment.Unsuitable Extinguishing MediaNo information available.

5.2. Special hazards arising from the substance or mixture

Thermal decomposition can lead to release of irritating gases and vapors.

5.3. Advice for firefighters

Wear self-contained breathing apparatus and protective suit. Use personal protective equipment.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

For non-emergency personnelEvacuate personnel to safe areas. Ensure adequate ventilation.For emergency respondersUse personal protection recommended in Section 8.

6.2. Environmental precautions

Do not flush into surface water or sanitary sewer system.

6.3. Methods and material for containment and cleaning up

Methods for containment	Prevent further leakage or spillage if safe to do so.
Methods for cleaning up	Use personal protective equipment. Cover powder spill with plastic sheet or tarp to minimize

spreading and keep powder dry. Take up mechanically, placing in appropriate containers for disposal. Avoid dust formation. Clean contaminated surface thoroughly.

6.4. Reference to other sections

See Sections 8 & 13 for additional information.

SECTION 7: Handling and storage

7.1. Precautions for safe handling

When using, do not eat, drink or smoke. Provide regular cleaning of equipment, work area and clothing. Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product. Keep away from food, drink and animal feeding stuffs.

7.2. Conditions for safe storage, including any incompatibilities

Keep container tightly closed in a dry and well-ventilated place.

7.3. Specific end use(s)

Use as a laboratory reagent.

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

8.2. Exposure controls

Appropriate engineering controls

Showers, eyewash stations, and ventilation systems.

Individual protection measures, such as personal protective equipment	
Eye/face protection	Tightly fitting safety goggles
Skin protection	
Hand protection	Impervious gloves.
Other	Impervious gloves. Impervious clothing.
Respiratory protection	In case of inadequate ventilation wear respiratory protection.

Environmental Exposure Controls

No information available.

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Physical state	Solid
Appearance	Powder
Color	yellow-orange
Odor	No information available
Odor Threshold	No information available
<u>Property</u> pH Melting point/freezing point Initial boiling point and boiling range Flash point Evaporation rate	<u>Values</u> 198-200 °C

<u>Remarks • Method</u> No information available

No information available

No information available. No information available

- Flammability (solid, gas) Upper flammability limit Lower flammability limit Vapor pressure Vapor density Relative density Solubility Partition coefficient: n-octanol/water Autoignition temperature Decomposition temperature Viscosity Explosive properties Oxidizing properties
- <u>9.2. Other information</u> Softening point Molecular Weight Solubility in other solvents VOC content Density

No information available No information available

No information available 532.57 g/mol Soluble in dimethyl sulfoxide (DMSO) @ 40 mg/mL No information available No information available.

SECTION 10: Stability and reactivity

10.1. Reactivity

No information available.

10.2. Chemical stability

Stable under normal conditions.

10.3. Possibility of hazardous reactions

Hazardous polymerizationHazardous polymerization does not occur.Hazardous reactionsNone under normal processing.

10.4. Conditions to avoid

Protect from light and heat.

10.5. Incompatible materials

Strong oxidizing agents.

10.6. Hazardous decomposition products

None under normal use conditions.

SECTION 11: Toxicological information

11.1. Information on toxicological effects

This material should only be handled by, or under the close supervision of, those properly qualified in the handling and use of potentially hazardous chemicals. It should be borne in mind that the toxicological and physiological properties of this compound is not well defined.

Information on likely routes of exposure

Inhalation	May cause irritation of respiratory tract.
Eye contact	Contact with eyes may cause irritation.

12328 Sunitinib

Skin contact Ingestion	May cause irritation. Target Organ Effects. Reproductive Toxicity.
Symptoms	Fatigue. Asthenia. Fever. Diarrhea. Nausea. Vomiting. Abdominal pain. Constipation. hypertension. Peripheral edema. rash. Dry skin. Headache. back pain. Arthralgia. Shortness of breath or cough. dyspnea. Anorexia. mucositis. indigestion. hand-foot syndrome. skin discoloration. altered taste. extremity pain. Bleeding.
Skin corrosion/irritation	No information available.
Serious eye damage/eye irritation	No information available.
Sensitization	No information available.
Mutagenic effects	Not mutagenic in AMES Test. Negative in an in vivo rat micronucleus test. Negative in the chromosomal aberration assay.
Carcinogenic effects	In rasH2 transgenic mice gastroduodenal carcinomas and/or gastric mucosal hyperplasia, as well as an increased incidence of background hemangiosarcomas were observed at doses of =25 mg/kg/day following daily dose administration of sunitinib in studies of 1 or 6 months duration. No proliferative changes were observed in rasH2 transgenic mice at 8 mg/kg/day. In a 2-year Sprague-Dawley rat carcinogenicity study, administration of sunitinib in 28-day cycles followed by 7-day dose-free periods resulted in findings of duodenal carcinoma at doses as low as 1 mg/kg/day. At the high dose of 3 mg/kg/day the incidence of duodenal tumors was increased and was accompanied by findings of gastric mucous cell hyperplasia and by an increased incidence of pheochromocytoma and hyperplasia of the adrenal.
Reproductive toxicity	This material is classified as a Pregnancy Category D: Positive evidence of risk. Effects on the female reproductive system were identified in a 3-month repeat dose monkey study (2, 6, 12 mg/kg/day), where ovarian changes were noted at 12 mg/kg/day while uterine changes (endometrial atrophy) were noted at 2 mg/kg/day. With the addition of vaginal atrophy, the uterine and ovarian effects were reproduced at 6 mg/kg/day in the 9-month monkey study. 1.5 mg/kg/day represents a no effect level in monkeys administered sunitinities for 9 months. In female rats, no fertility effects were observed at doses of 5.0 mg/kg/day administered for 21 days up to gestational day 7, however significant embryolethality was observed at the 5.0 mg/kg dose. No reproductive effects were observed in male rats dosed (1, 3 or 10 mg/kg/day) for 58 days prior to mating with untreated females. Fertility, copulation, conception indices, and sperm evaluation (morphology, concentration, and motility) were unaffected by sunitinib at doses 10 mg/kg/day.
STOT - single exposure	No information available.
STOT - repeated exposure	Hepatotoxicity (including liver failure), cardiac toxicity and cardiac failure (left ventricular ejection fraction declines to below the lower limit of normal, prolonged QT intervals, torsade de pointes), osteonecrosis of the jaw, thyroid dysfunction, hypoglycemia and Stevens-Johnson syndrome or toxic epidermal necrolysis.
Aspiration Hazard	No information available.
Other information	No information available.

SECTION 12: Ecological information

12.1. Toxicity

No information available.

12.2. Persistence and degradability

No information available.

12.3. Bioaccumulative potential

Bioaccumulation	No information available.
Bioconcentration factor (BCF)	No information available.

12.4. Mobility in soil

No information available.

12.5. Results of PBT and vPvB assessment

No information available.

12.6. Other adverse effects

No information available

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Waste from residues / unused products	Dispose of in accordance with local regulations.
Contaminated packaging	Empty containers should be taken to an approved waste handling site for recycling or disposal.
Other information	According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user based on the application for which the product was used.

SECTION 14: Transport information

IMDG/IMO 14.1 UN number 14.2 UN proper shipping name 14.3 Transport hazard class(es) 14.4 Packing group 14.5 Environmental hazards 14.6 Special precautions for user 14.7 Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code	Not regulated Not regulated Not regulated None None Not regulated
ADR/RID 14.1 UN number 14.2 UN proper shipping name 14.3 Transport hazard class(es) 14.4 Packing group 14.5 Environmental hazards 14.6 Special precautions for user	Not regulated Not regulated Not regulated None None
IATA 14.1 UN number 14.2 UN proper shipping name 14.3 Transport hazard class(es) 14.4 Packing group 14.5 Environmental hazards 14.6 Special precautions for user	Not regulated Not regulated Not regulated Not regulated None None

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Candidate List of Substances of Very High Concern for Authorization Information

This product does not contain Substances of Very High Concern (SVHC).

SEVESO Directive Information

This product does not contain substances identified in the SEVESO Directive.
International inventories
TSCA 8(b)
-

DSL/NDSL	-
EINECS/ELINCS	-
ENCS	-
IECSC	-
KECL	-
PICCS	-
AICS	-

International inventories legend

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

EINECS/ELINCS - European Inventory of Existing Commercial Chemical Substances/EU List of Notified Chemical Substances

ENCS - Japan Existing and New Chemical Substances

IECSC - China Inventory of Existing Chemical Substances

KECL - Korean Existing and Evaluated Chemical Substances

PICCS - Philippines Inventory of Chemicals and Chemical Substances

AICS - Australian Inventory of Chemical Substances

15.2. Chemical safety assessment

For this substance a chemical safety assessment has not been carried out

SECTION 16: Other information

Full text of H-Statements referred to under Sections 2 and 3

H360Df - May damage the unborn child. Suspected of damaging fertility H372 - Causes damage to organs through prolonged or repeated exposure if swallowed

Classification procedure:	Expert judgment and weight of evidence determination.
Issuing Date:	2015-01-15
Revision Date:	2018-03-26
Disclaimer	

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.